How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals?

Abbreviations anti‐HBs antibody to hepatitis B surface antigen CHB chronic hepatitis B HBsAg hepatitis B surface antigen HBV hepatitis B virus IFN interferon NAP nucleic acid polymer NUC nucleos(t)ide PEG‐IFN pegylated interferon TDF tenofovir disoproxyl fumarate The achievement of hepatitis B surfa...

Full description

Saved in:
Bibliographic Details
Published inHepatology communications Vol. 4; no. 1; pp. 5 - 7
Main Authors Loglio, Alessandro, Lampertico, Pietro
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.01.2020
John Wiley and Sons Inc
Wolters Kluwer Health/LWW
Subjects
Antigens
Deoxyribonucleic acid
DNA
Hepatitis
Hepatitis B
Interferon
Studies
Online AccessGet full text

Cover

More Information
Summary:Abbreviations anti‐HBs antibody to hepatitis B surface antigen CHB chronic hepatitis B HBsAg hepatitis B surface antigen HBV hepatitis B virus IFN interferon NAP nucleic acid polymer NUC nucleos(t)ide PEG‐IFN pegylated interferon TDF tenofovir disoproxyl fumarate The achievement of hepatitis B surface antigen (HBsAg) loss and its durability off treatment are of paramount importance for current and future anti‐hepatitis B virus (HBV) strategies. Because HBsAg loss is a rare event, multicenter studies and pooled analyses may be instrumental, as demonstrated by Lok et al. in this issue of Hepatology Communications. [...]the combination of TDF and PEG‐IFN increased the rates of HBsAg loss compared to TDF monotherapy. [...]this study sheds new light on the durability of HBsAg loss in patients with CHB treated with TDF or in combination with PEG‐IFN, findings that are in line with what has been described in other studies and during the natural history of HBV.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
SEE ARTICLE ON PAGE https://doi.org/10.1002/hep4.1436
Potential conflict of interest: Dr. Lampertico advises and is on the speakers’ bureau for Janssen, MYR Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, AbbVie, Roche, Eiger, Alnylam, Bristol‐Myers Squibb, and Merck Sharp & Dohme. Dr. Loglio is on the speakers’ bureau for MYR Pharmaceuticals and Gilead.
ISSN:2471-254X
2471-254X
DOI:10.1002/hep4.1476